Buttery Sara C, Williams Parris J, Alghamdi Saeed M, Philip Keir E J, Perkins Alexis, Kallis Constantinos, Quint Jennifer K, Polkey Michael I, Breuls Sofie, Buekers Joren, Chynkiamis Nikolaos, Delgado-Ortiz Laura, Demeyer Heleen, Frei Anja, Garcia-Aymerich Judith, Gimeno-Santos Elena, Koch Sarah, Megaritis Dimitrios, Polhemus Ashley, Troosters Thierry, Vogiatzis Ioannis, Watz Henrik, Hopkinson Nicholas S
National Heart and Lung Institute, Imperial College London, London, UK
Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, UK.
Eur Respir Rev. 2023 Nov 22;32(170). doi: 10.1183/16000617.0134-2023. Print 2023 Dec 31.
Reduced mobility is a central feature of COPD. Assessment of mobility outcomes that can be measured digitally (digital mobility outcomes (DMOs)) in daily life such as gait speed and steps per day is increasingly possible using devices such as pedometers and accelerometers, but the predictive value of these measures remains unclear in relation to key outcomes such as hospital admission and survival.
We conducted a systematic review, nested within a larger scoping review by the MOBILISE-D consortium, addressing DMOs in a range of chronic conditions. Qualitative and quantitative analysis considering steps per day and gait speed and their association with clinical outcomes in COPD patients was performed.
21 studies (6076 participants) were included. Nine studies evaluated steps per day and 11 evaluated a measure reflecting gait speed in daily life. Negative associations were demonstrated between mortality risk and steps per day (per 1000 steps) (hazard ratio (HR) 0.81, 95% CI 0.75-0.88, p<0.001), gait speed (<0.80 m·s) (HR 3.55, 95% CI 1.72-7.36, p<0.001) and gait speed (per 1.0 m·s) (HR 7.55, 95% CI 1.11-51.3, p=0.04). Fewer steps per day (per 1000) and slow gait speed (<0.80 m·s) were also associated with increased healthcare utilisation (HR 0.80, 95% CI 0.72-0.88, p<0.001; OR 3.36, 95% CI 1.42-7.94, p=0.01, respectively). Available evidence was of low-moderate quality with few studies eligible for meta-analysis.
Daily step count and gait speed are negatively associated with mortality risk and other important outcomes in people with COPD and therefore may have value as prognostic indicators in clinical trials, but the quantity and quality of evidence is limited. Larger studies with consistent methodologies are called for.
活动能力下降是慢性阻塞性肺疾病(COPD)的核心特征。使用计步器和加速度计等设备,越来越有可能在日常生活中对可通过数字测量的活动能力结果(数字活动能力结果,DMOs)进行评估,如步速和每日步数,但这些测量指标对于诸如住院和生存等关键结果的预测价值仍不明确。
我们开展了一项系统评价,该评价嵌套于MOBILISE-D联盟进行的一项更大范围的综述中,涉及一系列慢性疾病中的DMOs。对COPD患者的每日步数、步速及其与临床结果的关联进行了定性和定量分析。
纳入21项研究(6076名参与者)。9项研究评估了每日步数,11项研究评估了反映日常生活中步速的指标。死亡率风险与每日步数(每1000步)(风险比(HR)0.81,95%置信区间0.75 - 0.88,p<0.001)、步速(<0.80 m·s)(HR 3.55,95%置信区间1.72 - 7.36,p<0.001)以及步速(每增加1.0 m·s)(HR 7.55,95%置信区间1.11 - 51.3,p = 0.04)之间呈负相关。每日步数较少(每1000步)和步速较慢(<0.80 m·s)也与医疗保健利用率增加相关(HR 0.80,95%置信区间0.72 - 0.88,p<0.001;OR 3.36,95%置信区间1.42 - 7.94,p = 0.01)。现有证据质量为低到中等,很少有研究符合荟萃分析的条件。
每日步数和步速与COPD患者的死亡风险及其他重要结果呈负相关,因此在临床试验中可能具有作为预后指标的价值,但证据的数量和质量有限。需要开展方法一致的更大规模研究。